Atossa Therapeutics (ATOS) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 11, 2021
Document Information [Line Items]
Entity Central Index Key	0001488039
Entity Registrant Name	ATOSSA THERAPEUTICS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-35610
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4753208
Entity Address, Address Line One	107 Spring Street
Entity Address, Postal Zip Code	98104
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
City Area Code	206
Local Phone Number	325-6086
Title of 12(b) Security	Common Stock, $0.18 par value
Trading Symbol	ATOS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		126,624,110

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 140,040,955	$ 39,553,671
Restricted cash	110,000	110,000
Prepaid expenses	1,883,197	1,813,902
Research and development tax rebate receivable	934,672	634,940
Other current assets	18,060	657,662
Total current assets	142,986,884	42,770,175
Furniture and equipment, net	22,138	20,632
Intangible assets, net	0	13,375
Right-of-use asset	1,217	18,053
Other assets	13,408	17,218
Total Assets	143,023,647	42,839,453
Current liabilities
Accounts payable	667,988	1,588,613
Accrued expenses	75,695	93,367
Payroll liabilities	912,670	963,665
Common stock warrant liability	0	13,003,075
Lease liability	1,217	18,053
Other current liabilities	18,251	4,748
Total current liabilities	1,675,821	15,671,521
Total Liabilities	1,675,821	15,671,521
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 584 and 621 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	1	1
Common stock - $0.18 par value; 175,000,000 shares authorized; 126,623,541 and 47,548,835 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	22,792,225	8,558,778
Additional paid-in capital	242,373,694	129,887,146
Accumulated deficit	(124,402,093)	(111,898,992)
Total Stockholders' Equity	141,347,826	27,167,932
Total Liabilities and Stockholders' Equity	143,023,647	42,839,453
Series B Preferred Stock [Member]
Stockholders' equity
Additional paid-in capital - Series B convertible preferred stock	$ 583,999	$ 620,999

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	584	621
Preferred stock, outstanding (in shares)	584	621
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	126,623,541	47,548,835
Common stock, outstanding (in shares)	126,623,541	47,548,835

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses
Research and development	$ 2,206,158	$ 1,659,075	$ 7,383,281	$ 4,250,934
General and administrative	2,952,436	1,849,741	8,309,807	6,130,698
Total operating expenses	5,158,594	3,508,816	15,693,088	10,381,632
Operating loss	(5,158,594)	(3,508,816)	(15,693,088)	(10,381,632)
Other income (expense), net	(38,551)	17,745	(81,374)	36,999
Loss before income taxes	(5,197,145)	(3,491,071)	(15,774,462)	(10,344,633)
Income taxes	0	0	0	0
Net loss	$ (5,197,145)	$ (3,491,071)	$ (15,774,462)	$ (10,344,633)
Loss per common share - basic and diluted (in dollars per share)	$ (0.04)	$ (0.34)	$ (0.14)	$ (1.09)
Weighted average shares outstanding - basic and diluted (in shares)	126,537,544	10,162,770	113,689,961	9,496,222

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock, Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member]Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member]Common Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member]Common Stock, Additional Paid-in Capital [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock, Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019									671		9,130,984
Balance at Dec. 31, 2019									$ 1	$ 670,999	$ 1,643,565	$ 104,912,480	$ (94,071,040)	$ 13,156,005
Compensation cost for stock options granted												687,752		687,752
Net loss													(2,947,420)	(2,947,420)
Balance (in shares) at Mar. 31, 2020									671		9,130,984
Balance at Mar. 31, 2020									$ 1	670,999	$ 1,643,565	105,600,232	(97,018,460)	10,896,337
Balance (in shares) at Dec. 31, 2019									671		9,130,984
Balance at Dec. 31, 2019									$ 1	670,999	$ 1,643,565	104,912,480	(94,071,040)	13,156,005
Net loss														$ (10,344,633)
Conversion of Series B convertible preferred stock to common stock (in shares)								(48)
Common stock issued for option exercises (in shares)														225,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)														225,000
Balance (in shares) at Sep. 30, 2020									623		10,464,250
Balance at Sep. 30, 2020									$ 1	622,999	$ 1,883,553	111,780,197	(104,415,673)	$ 9,871,077
Balance (in shares) at Mar. 31, 2020									671		9,130,984
Balance at Mar. 31, 2020									$ 1	670,999	$ 1,643,565	105,600,232	(97,018,460)	10,896,337
Compensation cost for stock options granted												1,036,484		1,036,484
Net loss													(3,906,142)	(3,906,142)
Issuance of common stock, net of issuance costs (in shares)											160,108
Issuance of common stock, net of issuance costs											$ 28,820	318,807		347,627
Conversion of Series B convertible preferred stock to common stock (in shares)				(45)		12,786
Conversion of Series B convertible preferred stock to common stock					$ (45,000)	$ 2,301	$ 42,699
Balance (in shares) at Jun. 30, 2020									626		9,303,878
Balance at Jun. 30, 2020									$ 1	625,999	$ 1,674,686	106,998,222	(100,924,602)	8,374,306
Compensation cost for stock options granted												663,593		663,593
Net loss													(3,491,071)	(3,491,071)
Issuance of common stock, net of issuance costs (in shares)											1,083,531
Issuance of common stock, net of issuance costs											$ 195,036	4,143,635		$ 4,338,671
Conversion of Series B convertible preferred stock to common stock (in shares)								(3)	(3)		853
Conversion of Series B convertible preferred stock to common stock										(3,000)	$ 154	2,846
Common stock issued for option exercises (in shares)											225,000			225,000
Common stock issued for option exercises											$ 40,500	500,600		$ 541,100
Shares withheld related to cashless exercise of options and taxes (in shares)											(149,012)
Shares withheld related to cashless exercise of options and taxes											$ (26,823)	(528,699)		$ (555,522)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)											225,000			225,000
Common stock issued for option exercise											$ 40,500	500,600		$ 541,100
Balance (in shares) at Sep. 30, 2020									623		10,464,250
Balance at Sep. 30, 2020									$ 1	622,999	$ 1,883,553	111,780,197	(104,415,673)	9,871,077
Balance (in shares) at Dec. 31, 2020									621		47,548,835
Balance at Dec. 31, 2020	$ 9,731,714	$ 3,271,361	$ 13,003,075						$ 1	620,999	$ 8,558,778	129,887,146	(111,898,992)	27,167,932
Compensation cost for stock options granted												639,751		639,751
Net loss													(3,538,069)	(3,538,069)
Conversion of Series B convertible preferred stock to common stock (in shares)				(1)		285
Conversion of Series B convertible preferred stock to common stock					(1,000)	$ 51	949
Issuance of common stock and warrants, net of issuance costs (in shares)											41,211,100
Issuance of common stock and warrants, net of issuance costs											$ 7,417,998	62,250,410		69,668,408
Issuance of common stock upon warrant exercise (in shares)											32,064,148
Issuance of common stock upon warrant exercise											$ 5,771,547	26,988,755		32,760,302
Balance (in shares) at Mar. 31, 2021									620		120,824,368
Balance at Mar. 31, 2021									$ 1	619,999	$ 21,748,374	229,498,725	(112,165,700)	139,701,399
Balance (in shares) at Dec. 31, 2020									621		47,548,835
Balance at Dec. 31, 2020	$ 9,731,714	$ 3,271,361	$ 13,003,075						$ 1	620,999	$ 8,558,778	129,887,146	(111,898,992)	27,167,932
Net loss														$ (15,774,462)
Conversion of Series B convertible preferred stock to common stock (in shares)								(37)
Common stock issued for option exercises (in shares)														699,410
Issuance of common stock upon warrant exercise (in shares)														37,452,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)														699,410
Balance (in shares) at Sep. 30, 2021									584		126,623,541
Balance at Sep. 30, 2021									$ 1	583,999	$ 22,792,225	242,373,694	(124,402,093)	$ 141,347,826
Balance (in shares) at Mar. 31, 2021									620		120,824,368
Balance at Mar. 31, 2021									$ 1	619,999	$ 21,748,374	229,498,725	(112,165,700)	139,701,399
Compensation cost for stock options granted												1,214,110		1,214,110
Net loss													(7,039,248)	(7,039,248)
Conversion of Series B convertible preferred stock to common stock (in shares)				(33)		9,377
Conversion of Series B convertible preferred stock to common stock					$ (33,000)	$ 1,688	$ 31,312
Issuance of common stock upon warrant exercise (in shares)											5,091,351
Issuance of common stock upon warrant exercise											$ 916,443	9,279,198		10,195,641
Balance (in shares) at Jun. 30, 2021									587		125,925,096
Balance at Jun. 30, 2021									$ 1	586,999	$ 22,666,505	240,023,345	(119,204,948)	144,071,902
Compensation cost for stock options granted												1,794,138		1,794,138
Net loss													(5,197,145)	$ (5,197,145)
Conversion of Series B convertible preferred stock to common stock (in shares)								(3)	(3)		854
Conversion of Series B convertible preferred stock to common stock										(3,000)	$ 154	2,846
Common stock issued for option exercises (in shares)											699,410			699,410
Common stock issued for option exercises											$ 125,894	1,596,679		$ 1,722,573
Shares withheld related to cashless exercise of options and taxes (in shares)											(297,829)
Shares withheld related to cashless exercise of options and taxes											$ (53,610)	(1,852,498)		(1,906,108)
Issuance of common stock and warrants, net of issuance costs											$ 296,010	809,184		$ 862,466
Issuance of common stock upon warrant exercise (in shares)														296,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)											699,410			699,410
Common stock issued for option exercise											$ 125,894	1,596,679		$ 1,722,573
Balance (in shares) at Sep. 30, 2021									584		126,623,541
Balance at Sep. 30, 2021									$ 1	$ 583,999	$ 22,792,225	$ 242,373,694	$ (124,402,093)	$ 141,347,826

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020
Issuance costs		$ 133,157	$ 178,544
Issuance of common stock and warrants, issuance costs	$ 5,493,310

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (15,774,462)	$ (10,344,633)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	3,647,999	2,387,829
Disposal of assets	0	4,149
Depreciation and amortization	21,265	37,265
Changes in operating assets and liabilities:
Prepaid expenses	(69,295)	(621,907)
Research and development tax rebate receivable	(299,732)	300,451
Other assets	643,412	(152,781)
Accounts payable	(920,625)	389,441
Accrued expenses	(17,672)	7,285
Payroll liabilities	(50,995)	(146,573)
Other current liabilities	13,503	1,779
Net cash used in operating activities	(12,806,602)	(8,137,695)
CASH FLOWS FROM INVESTING ACTIVITY
Purchase of furniture and equipment	(9,396)	(9,367)
Net cash used in investing activities	(9,396)	(9,367)
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from issuance of common stock, net of issuance costs	0	4,686,298
Proceeds from issuance of common stock and warrants, net of issuance costs	69,668,408	0
Payment of taxes related to net-exercise of employee stock options	(574,867)	(14,422)
Proceeds from exercise of employee stock options	391,332	0
Proceeds from exercise of warrants	43,818,409	0
Net cash provided by financing activities	113,303,282	4,671,876
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	100,487,284	(3,475,186)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	39,663,671	12,691,136
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	140,150,955	9,215,950
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	140,040,955	9,105,950
Restricted cash	110,000	110,000
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	140,150,955	9,215,950
NONCASH INVESTING AND FINANCING ACTIVITIES
Common stock issued upon cashless exercise of stock options	1,331,241	541,100
Reclassification of the warrant liability to equity upon adoption of accounting standard	13,003,075	0
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES
Conversion of convertible preferred stock to common stock	$ 37,000	$ 48,000

Note 1 - Nature of Operations

Note 1 - Nature of Operations	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: On January 6, 2020, Atossa Therapeutics, Inc. (the “Company”) was incorporated on April 30, 2009, 19" December 31. Impact of the Novel Coronavirus The continued spread of the COVID- 19 may third H201, 301 19 may 19 may may not may 19 may not not 301 H201. 2 19 19 19 19 may 19 not third 19 In response to the COVID- 19 March 27, 2020. March 11, 2021, 2021, 19 not may

Note 2 - Liquidity and Capital

Note 2 - Liquidity and Capital Resources	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Liquidity and Capital Resources [Text Block]	NOTE 2: The Company has incurred net losses and negative operating cash flows since inception. For the nine September 30, 2021, September 30, 2021, not 113,486,817 first nine 2021, one no may

Note 3 - Summary of Accounting

Note 3 - Summary of Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2020. not In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three nine September 30, 2021, not may December 31, 2021. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Research and Development Expense Research and development ("R&D") costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expenses for the Company's drugs under development, expenses associated with clinical trials and associated salaries and benefits. R&D expenses also include an allocation of the CEO's salary and related benefits including bonus and non-cash stock-based compensation expense based on an estimate of total hours expended on research and development activities. The Company’s CEO is involved in the development of the Company’s drug candidates and oversight of the related clinical trial activity. Fair Value Measurements The Company records financial assets and liabilities measured on a recurring and non-recurring basis as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across three 1 2 3 8. Stock-based Payments The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense is based on the estimated grant date fair value and is recognized as an expense over the requisite service period. The Company has made a policy election to recognize forfeitures when they occur. The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and estimation of an appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The Company has elected the simplified method for the expected life assumption for stock option grants, which averages the contractual term of the options of ten one four not zero no Financial Instruments with Characteristics of Both Liabilities and Equity During December 2020, Recent Accounting Pronouncements On May 3, 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options December 15, 2021, Recently Adopted Accounting Pronouncements On January 1, 2021, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity (Topic 815 December 15, 2023, not December 15, 2020. The guidance removes the liability and equity separation models for convertible instruments with a cash conversion feature or beneficial conversion feature. As a result, companies will more likely account for convertible debt instruments wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e. as a single unit of account). In addition, the guidance simplifies the settlement assessment that issuers perform to determine whether a contract in their own equity qualifies for equity classification. Finally, the guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments. The cumulative effect of initially applying the new standard was recognized as an adjustment to accumulated deficit. Upon the adoption of the new standard, we recognized the following adjustments: Ending Balance as of December 31, 2020 ASU 2020-06 Adjustments Beginning Balance as of January 1, 2021 Warrant liability $ 13,003,075 $ (13,003,075 ) $ - Additional paid-in capital 129,887,146 9,731,714 139,618,860 Accumulated deficit (111,898,992 ) 3,271,361 (108,627,631 ) The $3,271,361 adjustment to accumulated deficit includes the reclassification of warrant financing expenses of $938,794 and the change in fair value of common stock warrants of $2,332,567 subsequent to initial recognition. On January 1, 2021, 2019 12, Income Taxes, (Topic 740 not

Note 4 - Restricted Cash

Note 4 - Restricted Cash	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Restricted Assets Disclosure [Text Block]	NOTE 4: The Company's restricted cash balance of $110,000 as of September 30, 2021 December 31, 2020

Note 5 - Prepaid Expenses

Note 5 - Prepaid Expenses	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Prepaid Expenses [Text Block]	NOTE 5: Prepaid expenses consisted of the following: As of September 30, As of December 31, 2021 2020 Prepaid research and development $ 1,567,871 $ 1,215,834 Prepaid insurance 136,880 417,854 Professional services 131,197 128,229 Financial exchange fees 14,500 - Retainer and security deposits 14,218 14,218 Prepaid rent 9,360 4,488 Other 9,171 33,279 Total prepaid expenses $ 1,883,197 $ 1,813,902

Note 6 - Research and Developme

Note 6 - Research and Development Tax Rebate Receivable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 6: On May 23, 2017, 1 2 19 nine September 30, 2021 2020, September 30, 2021 December 31, 2020, The Company had realized losses on foreign currency exchange during the three nine September 30, 2021 three nine September 30, 2020

Note 7 - Payroll Liabilities

Note 7 - Payroll Liabilities	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 7: Payroll liabilities consisted of the following: As of September 30, As of December 31, 2021 2020 Accrued bonuses $ 631,394 $ 689,635 Accrued vacation 173,430 171,112 Accrued payroll 107,846 102,918 Total payroll liabilities $ 912,670 $ 963,665

Note 8 - Fair Value of Financia

Note 8 - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 8: Pursuant to the accounting guidance for fair value measurement and its subsequent updates, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. The accounting guidance establishes a hierarchy for inputs used in measuring fair value that minimizes the use of unobservable inputs by requiring the use of observable market data when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on active market data. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The fair value hierarchy is broken down into the three ● Level 1 1 ● Level 2 2 ● Level 3 no Warrants issued in the financing transaction that closed on December 11, 2020 December 28, 2020 may not not 3 December 31, 2020. The following tables present the Company’s fair value hierarchy for all its financial assets and liabilities, by major security type measured at fair value on a recurring basis: September 30, 2021 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 51,794,857 $ 51,794,857 $ - $ - December 31, 2020 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 1,789,401 $ 1,789,401 $ - $ - Liabilities: Common stock warrant liability $ 13,003,075 $ - $ - $ 13,003,075 The following table summarizes the changes in the Company’s Level 3 nine September 30, 2021: Warrant Liability Beginning balance $ 13,003,075 Reclassification to equity upon adoption of accounting standard (13,003,075 ) Issuance of warrants - Change in fair value - Ending balance $ - The carrying amounts of our cash and cash equivalents, restricted cash, research and development tax rebate receivable, prepaid expenses, other current assets, accounts payable, accrued expenses, payroll liabilities and other current liabilities approximate their fair values due to their short-term maturities at September 30, 2021 December 31, 2020.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9: The Company is authorized to issue a total of 185,000,000 shares of stock consisting of 175,000,000 shares of common stock, par value $0.18 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares of Series A convertible preferred stock, par value $0.001 per share, 25,000 shares of Series B convertible preferred stock, par value $0.001 and 5,425 shares of Series C convertible preferred stock, par value $0.001 per share, through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock, no shares of Series A convertible preferred stock and no shares of Series C convertible preferred stock are outstanding as of September 30, 2021 December 31, 2020. 2021 On January 6, 2021, one 1933, January 8, 2021 On March 22, 2021, one 0.75 3 No. 333 255411 13,020,825 April 29, 2021. 2021 Warrants The terms and conditions of the warrants included in the 2021 Exercisability 4.5 The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the Company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction. Cashless Exercise no not may Exercise Price $1.055 January 2021 $2.88 March 2021 not may no Transferability may may Exchange Listing not Rights as Stockholder not Warrants Outstanding As of September 30, 2021, Outstanding Warrants to Purchase Shares Exercise Price Expiration date May 2018 warrants 762,344 $ 4.05 May 30, 2022 December 2020 warrants 6,489,500 $ 1.00 December 11, 2024-June 21, 2025 January 2021 warrants 4,500,000 $ 1.055 July 8, 2025 March 2021 warrants 10,525,000 $ 2.88 September 22, 2025 22,276,844 Warrant Activity During the three nine September 30, 2021, three nine September 30, 2021 no three nine September 30, 2020. Conversion of Series B Convertible Preferred Stock During the three nine September 30, 2021, three nine September 30, 2020,

Note 10 - Net Loss Per Share

Note 10 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 10: The Company follows the two two two Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, they have been excluded from the calculation. The Company’s common stock warrants and preferred stock contractually entitles the holders of such securities to participate in dividends but do not not not three nine September 30, 2021 2020. The following table summarizes the Company’s calculation of net loss per common share: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator Net loss attributable to common shareholders $ (5,197,145 ) $ (3,491,071 ) $ (15,774,462 ) $ (10,344,633 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 126,537,544 10,162,770 113,689,961 9,496,222 Net loss per share of common stock, basic and diluted: $ (0.04 ) $ (0.34 ) $ (0.14 ) $ (1.09 ) The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share, because including them would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Options to purchase common stock 10,043,575 7,158,387 8,682,997 5,825,082 Series B convertible preferred stock 166,142 177,562 172,909 183,544 Warrants to purchase common stock 22,356,105 1,070,028 24,773,777 1,070,028 32,565,822 8,405,977 33,629,683 7,078,654

Note 11 - Income Taxes

Note 11 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 11: Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of September 30, 2021 December 31, 2020,

Note 12 - Concentration of Cred

Note 12 - Concentration of Credit Risk	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 12: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. September 30, 2021 December 31, 2020,

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 13: Lease Commitments The Company evaluates all contractual agreements at inception to determine if they contain a lease. Lease liabilities are measured at present value of lease payments not The Company's operating lease assets consist of a copier system lease and an office lease. Our office lease expired on February 28, 2021. March 1, 2021, 12 19, October 2021. None three nine September 30, 2021 2020, September 30, 2021, As of September 30, 2021, 2021. September 30, 2021, three nine September 30, 2021 2020 The Company had lease expense under short term leases of $6,931 and $19,100, during the three nine September 30, 2021 2020 Litigation and Contingencies We are subject to legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not

Note 14 - Stock Based Compensat

Note 14 - Stock Based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 14: Stock Option and Incentive Plan On March 24, 2020, 2020 "2020 No may 2020 10 2020 May14, 2021 2020 The Company granted 175,000 and 3,818,921 options to purchase shares of common stock during the three nine September 30, 2021, three nine September 30, 2020, three nine September 30, 2021 three nine September 30, 2020 2020 September 30, 2021. may no 2010 "2010 The fair value of the stock options granted for the nine September 30, 2021 2020 Period ended September 30, 2021 2020 Risk-free interest rate 0.89% 1.08% 0.28% 0.47% Expected term (in years) 5.31-6.17 4.50-6.18 Dividend yield - - Expected volatility 122% 130% 103% 129% Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $1,794,138 and $3,647,999 for the three nine September 30, 2021 three nine September 30, 2020, Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 General and administrative $ 1,231,590 $ 489,853 $ 2,534,117 $ 1,675,414 Research and development 562,548 173,740 1,113,882 712,415 Total stock compensation expense $ 1,794,138 $ 663,593 $ 3,647,999 $ 2,387,829 Options issued and outstanding as of September 30, 2021 2020 2010 nine Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2021 7,067,436 $ 2.74 - Granted 3,818,921 2.98 - 99,800 Exercised (699,410 ) 2.46 - 2,753,652 Forfeited (75,000 ) 3.05 - - Expired (223 ) 225.00 - - Outstanding as of September 30, 2021 10,111,724 2.84 8.53 $ 11,697,962 Exercisable as of September 30, 2021 5,663,935 2.94 7.87 $ 9,039,985 Vested and expected to vest 10,111,724 $ 2.84 8.53 $ 11,697,962 At September 30, 2021

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2020. not In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three nine September 30, 2021, not may December 31, 2021.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense Research and development ("R&D") costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expenses for the Company's drugs under development, expenses associated with clinical trials and associated salaries and benefits. R&D expenses also include an allocation of the CEO's salary and related benefits including bonus and non-cash stock-based compensation expense based on an estimate of total hours expended on research and development activities. The Company’s CEO is involved in the development of the Company’s drug candidates and oversight of the related clinical trial activity.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company records financial assets and liabilities measured on a recurring and non-recurring basis as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across three 1 2 3 8.
Share-based Payment Arrangement [Policy Text Block]	Stock-based Payments The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense is based on the estimated grant date fair value and is recognized as an expense over the requisite service period. The Company has made a policy election to recognize forfeitures when they occur. The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and estimation of an appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The Company has elected the simplified method for the expected life assumption for stock option grants, which averages the contractual term of the options of ten one four not zero no
Financial Instruments with Characteristics of Both Liabilities and Equity, Policy [Policy Text Block]	Financial Instruments with Characteristics of Both Liabilities and Equity During December 2020,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements On May 3, 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options December 15, 2021, Recently Adopted Accounting Pronouncements On January 1, 2021, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity (Topic 815 December 15, 2023, not December 15, 2020. The guidance removes the liability and equity separation models for convertible instruments with a cash conversion feature or beneficial conversion feature. As a result, companies will more likely account for convertible debt instruments wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e. as a single unit of account). In addition, the guidance simplifies the settlement assessment that issuers perform to determine whether a contract in their own equity qualifies for equity classification. Finally, the guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments. The cumulative effect of initially applying the new standard was recognized as an adjustment to accumulated deficit. Upon the adoption of the new standard, we recognized the following adjustments: Ending Balance as of December 31, 2020 ASU 2020-06 Adjustments Beginning Balance as of January 1, 2021 Warrant liability $ 13,003,075 $ (13,003,075 ) $ - Additional paid-in capital 129,887,146 9,731,714 139,618,860 Accumulated deficit (111,898,992 ) 3,271,361 (108,627,631 ) The $3,271,361 adjustment to accumulated deficit includes the reclassification of warrant financing expenses of $938,794 and the change in fair value of common stock warrants of $2,332,567 subsequent to initial recognition. On January 1, 2021, 2019 12, Income Taxes, (Topic 740 not

Note 3 - Summary of Accountin_2

Note 3 - Summary of Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Accounting Standards Update and Change in Accounting Principle [Table Text Block]	Ending Balance as of December 31, 2020 ASU 2020-06 Adjustments Beginning Balance as of January 1, 2021 Warrant liability $ 13,003,075 $ (13,003,075 ) $ - Additional paid-in capital 129,887,146 9,731,714 139,618,860 Accumulated deficit (111,898,992 ) 3,271,361 (108,627,631 )

Note 5 - Prepaid Expenses (Tabl

Note 5 - Prepaid Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	As of September 30, As of December 31, 2021 2020 Prepaid research and development $ 1,567,871 $ 1,215,834 Prepaid insurance 136,880 417,854 Professional services 131,197 128,229 Financial exchange fees 14,500 - Retainer and security deposits 14,218 14,218 Prepaid rent 9,360 4,488 Other 9,171 33,279 Total prepaid expenses $ 1,883,197 $ 1,813,902

Note 7 - Payroll Liabilities (T

Note 7 - Payroll Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of September 30, As of December 31, 2021 2020 Accrued bonuses $ 631,394 $ 689,635 Accrued vacation 173,430 171,112 Accrued payroll 107,846 102,918 Total payroll liabilities $ 912,670 $ 963,665

Note 8 - Fair Value of Financ_2

Note 8 - Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	September 30, 2021 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 51,794,857 $ 51,794,857 $ - $ - December 31, 2020 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 1,789,401 $ 1,789,401 $ - $ - Liabilities: Common stock warrant liability $ 13,003,075 $ - $ - $ 13,003,075
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant Liability Beginning balance $ 13,003,075 Reclassification to equity upon adoption of accounting standard (13,003,075 ) Issuance of warrants - Change in fair value - Ending balance $ -

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding Warrants to Purchase Shares Exercise Price Expiration date May 2018 warrants 762,344 $ 4.05 May 30, 2022 December 2020 warrants 6,489,500 $ 1.00 December 11, 2024-June 21, 2025 January 2021 warrants 4,500,000 $ 1.055 July 8, 2025 March 2021 warrants 10,525,000 $ 2.88 September 22, 2025 22,276,844

Note 10 - Net Loss Per Share (T

Note 10 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator Net loss attributable to common shareholders $ (5,197,145 ) $ (3,491,071 ) $ (15,774,462 ) $ (10,344,633 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 126,537,544 10,162,770 113,689,961 9,496,222 Net loss per share of common stock, basic and diluted: $ (0.04 ) $ (0.34 ) $ (0.14 ) $ (1.09 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Options to purchase common stock 10,043,575 7,158,387 8,682,997 5,825,082 Series B convertible preferred stock 166,142 177,562 172,909 183,544 Warrants to purchase common stock 22,356,105 1,070,028 24,773,777 1,070,028 32,565,822 8,405,977 33,629,683 7,078,654

Note 14 - Stock Based Compens_2

Note 14 - Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Period ended September 30, 2021 2020 Risk-free interest rate 0.89% 1.08% 0.28% 0.47% Expected term (in years) 5.31-6.17 4.50-6.18 Dividend yield - - Expected volatility 122% 130% 103% 129%
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2021 7,067,436 $ 2.74 - Granted 3,818,921 2.98 - 99,800 Exercised (699,410 ) 2.46 - 2,753,652 Forfeited (75,000 ) 3.05 - - Expired (223 ) 225.00 - - Outstanding as of September 30, 2021 10,111,724 2.84 8.53 $ 11,697,962 Exercisable as of September 30, 2021 5,663,935 2.94 7.87 $ 9,039,985 Vested and expected to vest 10,111,724 $ 2.84 8.53 $ 11,697,962
Share-based Payment Arrangement, Option [Member]
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 General and administrative $ 1,231,590 $ 489,853 $ 2,534,117 $ 1,675,414 Research and development 562,548 173,740 1,113,882 712,415 Total stock compensation expense $ 1,794,138 $ 663,593 $ 3,647,999 $ 2,387,829

Note 2 - Liquidity and Capita_2

Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Net Income (Loss) Attributable to Parent, Total	$ (5,197,145)	$ (7,039,248)	$ (3,538,069)	$ (3,491,071)	$ (3,906,142)	$ (2,947,420)	$ (15,774,462)	$ (10,344,633)
Net Cash Provided by (Used in) Operating Activities, Total							(12,806,602)	(8,137,695)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	140,040,955			$ 9,105,950			140,040,955	$ 9,105,950	$ 39,553,671
Working Capital (Deficit)	$ 141,311,063						141,311,063
Proceeds from Issuance or Sale of Equity, Total							$ 113,486,817

Note 3 - Summary of Accountin_3

Note 3 - Summary of Accounting Policies (Details Textual) - USD ($)	Jan. 01, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Stockholders' Equity Attributable to Parent, Ending Balance		$ 141,347,826	$ 144,071,902	$ 139,701,399	$ 27,167,932	$ 9,871,077	$ 8,374,306	$ 10,896,337	$ 13,156,005
Retained Earnings [Member]
Stockholders' Equity Attributable to Parent, Ending Balance		$ (124,402,093)	$ (119,204,948)	$ (112,165,700)	(111,898,992)	$ (104,415,673)	$ (100,924,602)	$ (97,018,460)	$ (94,071,040)
Cumulative Effect, Period of Adoption, Adjustment [Member]
Stockholders' Equity Attributable to Parent, Ending Balance					13,003,075
Cumulative Effect, Period of Adoption, Adjustment [Member] | Retained Earnings [Member]
Stockholders' Equity Attributable to Parent, Ending Balance					$ 3,271,361
Accounting Standards Update 2020-06 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Stockholders' Equity Attributable to Parent, Ending Balance	$ 13,003,075
Reclassification of Warrant Financing Expenses	938,794
Fair Value Adjustment of Warrants	2,332,567
Accounting Standards Update 2020-06 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Retained Earnings [Member]
Stockholders' Equity Attributable to Parent, Ending Balance	$ 3,271,361
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term (Year)		1 year
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term (Year)		4 years
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years

Note 3 - Summary of Accountin_4

Note 3 - Summary of Accounting Policies - New Accounting Standards Adoption (Details) - USD ($)	Sep. 30, 2021	Jan. 01, 2021	Dec. 31, 2020
Warrant liability	$ 0	$ 0	$ 13,003,075
Additional paid-in capital		139,618,860	129,887,146
Accumulated deficit	$ (124,402,093)	(108,627,631)	$ (111,898,992)
Accounting Standards Update 2020-06 [Member]
Warrant liability		(13,003,075)
Additional paid-in capital		9,731,714
Accumulated deficit		$ 3,271,361

Note 4 - Restricted Cash (Detai

Note 4 - Restricted Cash (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Restricted Cash and Cash Equivalents, Total	$ 110,000	$ 110,000	$ 110,000

Note 5 - Prepaid Expenses - Sch

Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Prepaid research and development	$ 1,567,871	$ 1,215,834
Prepaid insurance	136,880	417,854
Professional services	131,197	128,229
Financial exchange fees	14,500	0
Retainer and security deposits	14,218	14,218
Prepaid rent	9,360	4,488
Other	9,171	33,279
Total prepaid expenses	$ 1,883,197	$ 1,813,902

Note 6 - Research and Develop_2

Note 6 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	May 23, 2017
Research and Development Tax Rebate Receivable	$ 934,672		$ 934,672		$ 634,940
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar						$ 0.435
Research and Development Tax Rebate Receivable, Additions			447,000	$ 439,000
Research and Development Tax Rebate Receivable	934,672		934,672		$ 634,940
Foreign Currency Transaction Gain (Loss), Realized	$ (34,930)	$ 17,745	$ (73,411)	$ 25,742

Note 7 - Payroll Liabilities -

Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accrued bonuses	$ 631,394	$ 689,635
Accrued vacation	173,430	171,112
Accrued payroll	107,846	102,918
Total payroll liabilities	$ 912,670	$ 963,665

Note 8 - Fair Value of Financ_3

Note 8 - Fair Value of Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Common stock warrant liability		$ 13,003,075
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability		0
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability		0
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability		13,003,075
Money Market Funds [Member]
Money market account	$ 51,794,857	1,789,401
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Money market account	51,794,857	1,789,401
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Money market account	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Money market account	$ 0	$ 0

Note 8 - Fair Value of Financ_4

Note 8 - Fair Value of Financial Instruments - Changes in Warrant Liability (Details) - Warrant Liability [Member]	9 Months Ended
	Sep. 30, 2021USD ($)
Beginning balance	$ 13,003,075
Reclassification to equity upon adoption of accounting standard	(13,003,075)
Issuance of warrants	0
Change in fair value	0
Ending balance	$ 0

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	Mar. 22, 2021	Jan. 08, 2021	Jan. 06, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Number of Shares Authorized to Issue (in shares)				185,000,000		185,000,000
Common Stock, Shares Authorized (in shares)				175,000,000		175,000,000		175,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.18		$ 0.18		$ 0.18
Preferred Stock, Shares Authorized (in shares)				10,000,000		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total (in shares)				584		584		621
Proceeds From Issuance of Common Stock and Warrants, Net of Issuance Costs						$ 69,668,408	$ 0
Class of Warrant or Right, Outstanding (in shares)				22,276,844		22,276,844
Proceeds from Warrant Exercises				$ 862,466	$ 0	$ 43,818,409	$ 0
Class of Warrant or Right, Exercised During Period (in shares)				296,000		37,452,000
Stock Issued During Period, Shares, Warrant Exercised (in shares)				296,000		37,452,000
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				3	3	37	48
Conversion of Stock, Shares Issued (in shares)				854	853	10,516	13,639
The 2021 Financing Transaction Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	13,020,825
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1		1
Warrants and Rights Outstanding, Term (Year)	4 years 6 months
Warrants and Rights Outstanding, Percent of Shares Sold Warrants May Call	75.00%
Warrants Exercisable, Ownership Percentage of Company’s Shares Allowed				4.99%		4.99%
Common Stock, Convertible, Ownership Percentage of Company’s Shares Allowed				9.99%		9.99%
The 2021 Financing Transaction [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.18		$ 0.18
Stock Issued During Period, Shares, New Issues (in shares)	17,361,100		23,850,000
Issuance of Common Stock and Warrants, Combined Purchase Price Per Share (in dollars per share)			$ 1.055
Stock Issuance Costs, Commission Fee Percent	7.00%		7.00%
Maximum Stock Issuance Expenses to Reimburse Placement Agent	$ 45,000		$ 45,000
Proceeds From Issuance of Common Stock and Warrants, Net of Issuance Costs	$ 46,400,000	$ 23,300,000
Shares Issued, Price Per Share (in dollars per share)	$ 2.88
The 2021 Financing Transaction [Member] | The 2021 Financing Transaction Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			17,887,500
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			0.75
Warrants and Rights Outstanding, Term (Year)			4 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.055
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				750,000		750,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total (in shares)				0		0		0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				4,000		4,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total (in shares)				0		0		0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				25,000		25,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001		$ 0.001
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				5,425		5,425
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total (in shares)				0		0		0

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Outstanding Warrants (Details)	Sep. 30, 2021$ / sharesshares
Outstanding Warrants to Purchase Shares (in shares)	22,276,844
The 2018 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	762,344
Exercise Price (in dollars per share) | $ / shares	$ 4.05
Expiration date	May 30, 2022
The 2020 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	6,489,500
Exercise Price (in dollars per share) | $ / shares	$ 1
The 2020 Warrants [Member] | Minimum [Member]
Expiration date	Dec. 11, 2024
The 2020 Warrants [Member] | Maximum [Member]
Expiration date	Jun. 21, 2025
January 2021 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	4,500,000
Exercise Price (in dollars per share) | $ / shares	$ 1.055
Expiration date	Jul. 8, 2025
March 2021 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	10,525,000
Exercise Price (in dollars per share) | $ / shares	$ 2.88
Expiration date	Sep. 22, 2025

Note 10 - Net Loss Per Share -

Note 10 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net loss attributable to common shareholders	$ (5,197,145)	$ (3,491,071)	$ (15,774,462)	$ (10,344,633)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted (in shares)	126,537,544	10,162,770	113,689,961	9,496,222
Net loss per share of common stock, basic and diluted: (in dollars per share)	$ (0.04)	$ (0.34)	$ (0.14)	$ (1.09)

Note 10 - Net Loss Per Share _2

Note 10 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Number of potential common shares excluded (in shares)	32,565,822	8,405,977	33,629,683	7,078,654
Share-based Payment Arrangement, Option [Member]
Number of potential common shares excluded (in shares)	10,043,575	7,158,387	8,682,997	5,825,082
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	166,142	177,562	172,909	183,544
Warrant [Member]
Number of potential common shares excluded (in shares)	22,356,105	1,070,028	24,773,777	1,070,028

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accrued Income Taxes, Total	$ 0	$ 0

Note 12 - Concentration of Cr_2

Note 12 - Concentration of Credit Risk (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Cash, Uninsured Amount	$ 139,850,220	$ 39,345,260

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Lessee, Operating Lease, Monthly Rent Payments			$ 750
Operating Lease, Expense	$ 3,500	$ 14,200	$ 16,800	$ 46,300
Operating Lease, Weighted Average Remaining Lease Term (Year)	1 year		1 year
Operating Lease, Weighted Average Discount Rate, Percent	11.30%		11.30%
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	$ 1,200		$ 1,200
Operating Lease, Payments	3,700	12,900	18,100	42,300
Short-term Lease, Cost	$ 6,931	$ 4,488	$ 19,100	$ 13,251

Note 14 - Stock Based Compens_3

Note 14 - Stock Based Compensation (Details Textual) - USD ($)	May 14, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 24, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		175,000	225,000	3,818,921	3,140,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)		699,410	225,000	699,410	225,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)		$ 2.46	$ 2.40	$ 2.46	$ 2.40
Share-based Payment Arrangement, Expense		$ 1,794,138	$ 663,593	$ 3,647,999	$ 2,387,829
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)		4,447,789		4,447,789
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 9,245,529		$ 9,245,529
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year 7 months 28 days
The 2020 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)						3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	15,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		11,926,079		11,926,079
The 2020 Stock Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense		$ 1,794,138	$ 663,593	$ 3,647,999	$ 2,387,829

Note 14 - Stock Based Compens_4

Note 14 - Stock Based Compensation - Valuation Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Dividend yield	0.00%	0.00%
Minimum [Member]
Risk-free interest rate	0.89%	0.28%
Expected term (in years) (Year)	5 years 3 months 21 days	4 years 6 months
Expected volatility	122.00%	103.00%
Maximum [Member]
Risk-free interest rate	1.08%	0.47%
Expected term (in years) (Year)	6 years 2 months 1 day	6 years 2 months 4 days
Expected volatility	130.00%	129.00%

Note 14 - Stock Based Compens_5

Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock compensation expense	$ 1,794,138	$ 663,593	$ 3,647,999	$ 2,387,829
General and Administrative Expense [Member]
Stock compensation expense	1,231,590	489,853	2,534,117	1,675,414
Research and Development Expense [Member]
Stock compensation expense	$ 562,548	$ 173,740	$ 1,113,882	$ 712,415

Note 14 - Stock Based Compens_6

Note 14 - Stock Based Compensation - Stock Option Activity (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Outstanding, shares (in shares)			7,067,436
Outstanding, weighted average exercise price per share (in dollars per share)			$ 2.74
Granted (in shares)	175,000	225,000	3,818,921	3,140,000
Granted, weighted average exercise price per share (in dollars per share)			$ 2.98
Granted, aggregate intrinsic value			$ 99,800
Exercised (in shares)	(699,410)	(225,000)	(699,410)	(225,000)
Exercised, weighted average exercise price per share (in dollars per share)	$ 2.46	$ 2.40	$ 2.46	$ 2.40
Exercised, aggregate intrinsic value			$ 2,753,652
Forfeited (in shares)			(75,000)
Forfeited, weighted average exercise price per share (in dollars per share)			$ 3.05
Expired (in shares)			(223)
Expired, weighted average exercise price per share (in dollars per share)			$ 225
Outstanding, shares (in shares)	10,111,724		10,111,724
Outstanding, weighted average exercise price per share (in dollars per share)	$ 2.84		$ 2.84
Outstanding, weighted average contractual life remaining in years (Year)			8 years 6 months 10 days
Outstanding, aggregate intrinsic value	$ 11,697,962		$ 11,697,962
Exercisable, shares (in shares)	5,663,935		5,663,935
Exercisable, Weighted average exercise price per share (in dollars per share)	$ 2.94		$ 2.94
Exercisable, weighted average contractual life remaining in years (Year)			7 years 10 months 13 days
Exercisable, aggregate intrinsic value	$ 9,039,985		$ 9,039,985
Vested and expected to vest, shares (in shares)	10,111,724		10,111,724
Vested and expected to vest, Weighted average exercise price per share (in dollars per share)	$ 2.84		$ 2.84
Vested and expected to vest, weighted average contractual life remaining in years (Year)			8 years 6 months 10 days
Vested and expected to vest, aggregate intrinsic value	$ 11,697,962		$ 11,697,962